$LBP1 Interim results of an open-label, multicentre, Phase 1/2 study to assess YTB323 (rapcabtagene autoleucel), a CAR T-cell therapy, for severe refractory systemic lupus erythematosus$

LBP1 Interim results of an open-label, multicentre, Phase 1/2 study to assess YTB323 (rapcabtagene autoleucel), a CAR T-cell therapy, for severe refractory systemic lupus erythematosus

Bibliographic Details
Main Authors:	Giulio Cavalli, Julia Weinmann-Menke, Clive Drakeford, Mi Kwon, Peter Gergely, Tamas Shisha, Pere Barba, Eva Wagner-Drouet, Josefina Cortés Hernández, José María Álvaro-Gracia Álvaro, Ozana Fischer, Beata Kovacs, Frédérique Chaperon, David Pearson, Tiina Kirsilä, Chih-Yung Sean Lee
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-03-01
Series:	Lupus Science and Medicine

LBP1 Interim results of an open-label, multicentre, Phase 1/2 study to assess YTB323 (rapcabtagene autoleucel), a CAR T-cell therapy, for severe refractory systemic lupus erythematosus

Similar Items